TY - JOUR ID - 3662 TI - Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around The Globe JO - International Journal of Health Policy and Management JA - IJHPM LA - en SN - AU - Oortwijn, Wija AU - Jansen, Maarten AU - Baltussen, Rob AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands Y1 - 2020 PY - 2020 VL - 9 IS - 1 SP - 27 EP - 33 KW - Health Technology Assessment KW - Evidence-Informed Deliberative Processes KW - Legitimate KW - Decision-Making KW - Guidance DO - 10.15171/ijhpm.2019.72 N2 - Background Evidence-informed deliberative processes (EDPs) were recently introduced to guide health technology assessment (HTA) agencies to improve their processes towards more legitimate decision-making. The EDP framework provides guidance that covers the HTA process, ie, contextual factors, installation of an appraisal committee, selecting health technologies and criteria, assessment, appraisal, and communication and appeal. The aims of this study were to identify the level of use of EDPs by HTA agencies, identify their needs for guidance, and to learn about best practices.   Methods A questionnaire for an online survey was developed based on the EDP framework, consisting of elements that reflect each part of the framework. The survey was sent to members of the International Network of Agencies for Health Technology Assessment (INAHTA). Two weeks following the invitation, a reminder was sent. The data collection took place between September-December 2018.   Results Contact persons from 27 member agencies filled out the survey (response rate: 54%), of which 25 completed all questions. We found that contextual factors to support HTA development and the critical elements regarding conducting and reporting on HTA are overall in place. Respondents indicated that guidance was needed for specific elements related to selecting technologies and criteria, appraisal, and communication and appeal. With regard to best practices, the Canadian Agency for Drugs and Technologies and the National Institute for Health and Care Excellence (NICE, UK) were most often mentioned.   Conclusion This is the first survey among HTA agencies regarding the use of EDPs and provides useful information for further developing a practical guide for HTA agencies around the globe. The results could support HTA agencies in improving their processes towards more legitimate decision-making, as they could serve as a baseline measurement for future monitoring and evaluation. UR - https://www.ijhpm.com/article_3662.html L1 - https://www.ijhpm.com/article_3662_f41c8acbddb95e0c6f5b621afc7bdbd3.pdf ER -